Adult Open Studies

Biology

LLUCC-BIOSPECIMEN LABORATORY - SPECIMEN COLLECTION
Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection Protocol
Mark E. Reeves, MD, PhD
Champions Oncology
Refer to separate attachment for list of "Tumors of High Interest"; this is included within the LLUCC Biospecimen Laboratory study above
Mark E. Reeves, MD, PhD

Breast

SWOG-NRG-BR009
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/ HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET) 
 
Roshni Narurkar, MD, MBBS 
Syndevrx SDX-0103
A Phase 1b/2 Study Assessing The Safety And Efficacy of Evexomostat (Sdx-7320) In Combination With The Pi3kα Inhibitor alpelisib (Piqray®) Plus Fulvestrant In Postmenopausal Women At Risk For Hyperglycemia With Advanced Breast Cancer And A Pik3ca Mutation Who Have Progressed On Or Following Endocrine Therapy Plus A Cdk4/6 Inhibitor
Gayathri Nagaraj, MD
EMBER-4 E-Lilly – J2J-MC-JZLH
A Randomized, Open Label, Phase 3 Study of Adjuvant imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have previously received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2-Early Breast Cancer with an Increased Risk of Recurrence.
https://classic.clinicaltrials.gov/ct2/show/NCT05514054
Gayathri Nagaraj, MD
SWOG -S2212
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast (SCARLET), A Randomized Phase III Study  
https://classic.clinicaltrials.gov/ct2/show/NCT05929768
Gayathri Nagaraj, MD
SWOG-S2206
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
https://clinicaltrials.gov/study/NCT06058377
Ami N. Patel, MD
Alliance-A012103
OptimICE PCR: De-Escalation of Therapy in Early -Stage TNBC Patients Who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
https://clinicaltrials.gov/ct2/show/NCT05812807
Ami N. Patel, MD
 

Germ Cell

4T-22-2-MAGESTIC
Phase II trial of serum Micro RNA-371 in detecting active germ cell tumors in patients with suspected regional disease –( MAGESTIC Trial: MiRNA in detecting Active Germ Cell tumors in Early Suspected and metastaTIC disease trial)
https://clinicaltrials.gov/study/NCT06060873/a>
Muhannad Alsyouf, MD

GI

Esophageal

Radiation Medicine
A phase II trial of proton-chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer
https://clinicaltrials.gov/ct2/show/NCT01684904
Gary Yang, MD

Pancreas

INV INT-Pancreatic - 5170277
A Phase II Trial of Pre-operative Chemotherapy (with Gemcitabine and Nab-paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients with Resectable Pancreatic Adenocarcinoma
https://www.clinicaltrials.gov/ct2/show/NCT03492671
Naveenraj Solomon, MD

Liver

Radiation Medicine
Phase I/II Trial of Stereotactic Body Proton Therapy (SBPT) for Patients with Liver Metastases 
https://clinicaltrials.gov/ct2/show/NCT01697371
Gary Yang, MD

Lung

NSCLC

SWOG-LUNGMAP
A Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
https://www.clinicaltrials.gov/ct2/show/NCT02154490
Hamid Mirshahidi, MD

NSCLC

SWOG-A081801
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
https://clinicaltrials.gov/ct2/show/NCT04267848
Hamid Mirshahidi, MD

NSCLC

SWOG-S1900J
A Phase II Study of Amivantamab SC (Subcutaneous) Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Lung Cancer (Lung-MAP Sub-Study)
https://clinicaltrials.gov/study/NCT06116682
Hamid Mirshahidi, MD

NSCLC

SWOG-S1800E
A Randomizerd Phase II/III Study of Docetaxel and Ramucinumab with or Without Cemiplimab (REGN2810) for Participants previously Treated with Platinumab-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Substudy)
https://clinicaltrials.gov/study/NCT06616584
Hamid Mirshahidi, MD

NSCLC

SWOG-S1900J
A Phase II Study of Amivantamab SC (Subcutaneous) Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Lung Cancer (Lung-MAP Sub-Study)
https://clinicaltrials.gov/study/NCT06116682
Hamid Mirshahidi, MD

NSCLC

SPFLIO - 174
A Phase 1b/2 multicenter open label platform study of select immunotherapy combinations in adult participants with previously untreated advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression
https://clinicaltrials.gov/study/NCT06162572?term=NCT06162572&rank=1
Hamid Mirshahidi, MD

NSCLC

SWOG-S1800E
A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or Without Ce4miplimab (REGN2810) for Participants previously Treated with Platinumab-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP)
https://clinicaltrials.gov/study/NCT06616584?term=S1800E&rank=1
Hamid Mirshahidi, MD

Melanoma

Castle Biosciences-CBI-2019-SLNBprosp-001
DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes DECIDE
https://clinicaltrials.gov/ct2/show/NCT02355587
Jukes Namm, MD

Multiple

COG-AGCT1532
A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with Intermediate and poor-risk metastatic germ cell tumors (Ages 26+ - Primary tumor arising in testis, ovary, retro-peritoneum or mediastinum)
Albert Kheradpour, MD

Solid Tumors

AMGEN-20190135-H
A Phase 1b Study Evaluating the Safety, Tolerability and Efficacy of AMG 510 (pINN Sotorasib) in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (Codebreak 101 Subprotocol H)
https://clinicaltrials.gov/study/NCT04185883
Hamid Mirshahidi, MD
INV-INT-PRESERVE
Phase II Randomized Single-Blinded Trial of Patient Reported Experiences with Sparing ExteRnal Oblique Fascia Vs Standard Inguinal OrchiEctomy (PRESERVE Trial)
https://clinicaltrials.gov/study/NCT06828185
CP-Start-001
A Phase 1/2 First- in -Human, Open -Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-Fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)
https://clinicaltrials.gov/search?term=CP%20-%20Start-001
John Shin, MD

Transplant & Cellular Therapy

PTLD

ATARA - ATA129-EBV-302
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
https://clinicaltrials.gov/ct2/show/NCT03394365
Dr. Sajad Khazal
P-CD19CD20-ALLO1
Open-Label, Multicenter, Phase I Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects with Selected Relapsed/Refractory B Cell Malignancies
https://clinicaltrials.gov/study/NCT06014762?term=P-CD19CD20-ALLO1
Dr. Sajad Khazal